NCT05984251View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CCX168 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

December 21, 2009

Primary Completion Date

September 19, 2010

Study Completion Date

April 11, 2011

Conditions
VasculitisSystemic Lupus Erythematosus (SLE)
Interventions
DRUG

CCX168

Administered orally.

DRUG

Placebo

Administered orally.

Trial Locations (1)

CH-4123

Covance Clinical Research Unit (CRU) AG, Allschwil

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY